Verona Pharma (VRP)

All online trades £12.50 plus an annual Management Fee of £35 & VAT with Selftrade. Apply

 3.88p
   
  • Change Today:
      0.000p
  • 52 Week High: 11.00p
  • 52 Week Low: 3.79p
  • Currency: UK Pounds
  • Shares Issued: 307.20m
  • Volume: 77,608
  • Market Cap: £11.90m
  • RiskGrade: 184
  • Beta: 0.73

Verona Pharma Overview

Verona Pharma is in the pharmaceuticals & biotechnology sector and is currently trading at 3.88p per share. In the last year Verona Pharma's share price has ranged from 3.79p to 11.00p and brokers are currently rating this stock as 'strong buy'.

1 Day Chart (25-05-2012)

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn n/a -8.0%
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue n/a 0.5
Pr/Book 2.9  
Latest F'cast
Revenue n/a n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Verona Pharma Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-07 n/a (1.22) (0.84)p n/a n/a n/a n/a 0.0%
31-Dec-08 n/a (1.34) (0.66)p n/a n/a n/a n/a 0.0%
31-Dec-09 n/a (1.60) (0.74)p n/a n/a n/a n/a 0.0%
31-Dec-10 n/a (1.89) (0.79)p n/a n/a n/a n/a 0.0%
31-Dec-11 n/a (1.84) (0.71)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Verona Pharma Forecasts

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Dec-12 25.00 (2.00) (0.65)p n/a n/a n/a n/a 0.0%
31-Dec-13 20.00 10.00 2.40p 1.6 n/a n/a n/a 0.0%

Copyright © 2012 FactSet Research Systems Inc. All rights reserved.

Verona Pharma Company Announcements

Posting of Annual Report 08-May-2012 16:56 PR Newswire
Verona Pharma appoints new CEO 01-May-2012 07:00 PR Newswire
Verona Pharma - Preliminary Unaudited Results 05-Apr-2012 07:00 PR Newswire

Verona Pharma ShareCast News

Small caps round-up: Verona Pharma, PHSC, Sterli... 26-Nov-2010 ShareCast
Cash burn remains low at Verona 04-Sep-2009 ShareCast

Verona Pharma Top Newspaper Links

Cracking hack bid 14-Nov-2007 Sun

Latest Verona Pharma Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 4: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 5: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 6: Forecast figures based on normalised accounts.

 

Verona Pharma Market Data

Currency UK Pounds
Share Price 3.88p
Change Today 0.000p
% Change 0.00 %
52 Week High 11.00p
52 Week Low 3.79p
Volume 77,608
Shares Issued 307.20m
Market Cap £11.90m
Beta 0.73
RiskGrade 184

Verona Pharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
38.61% below the market average38.61% below the market average38.61% below the market average38.61% below the market average38.61% below the market average
2.13% below the sector average2.13% below the sector average2.13% below the sector average2.13% below the sector average2.13% below the sector average
Price Trend
87.72% below the market average87.72% below the market average87.72% below the market average87.72% below the market average87.72% below the market average
96.43% below the sector average96.43% below the sector average96.43% below the sector average96.43% below the sector average96.43% below the sector average
Income Not Available
Growth Not Available

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Verona Pharma Dividends

No dividends found

Trades for 25-May-2012

Time Volume / Share Price
14:09 823 @ 3.79p
08:01 76,785 @ 3.99p

Verona Pharma Key Personnel

Chair Clive Page
CEO Michael Walker

Top of Page